Liquidia Insider Sold Shares Worth $1,986,695, According to a Recent SEC Filing
An insider at Liquidia recently sold shares valued at $1,986,695. This transaction was disclosed in a recent SEC filing, indicating a significant sale by a company insider.
Fund tied to Liquidia (LQDA) director sells 25K common shares
A fund associated with Liquidia Corp (LQDA) director Stephen M. Bloch, Canaan VIII L.P., sold a total of 25,000 common shares in open-market transactions for approximately $79-$80 per share. Despite these sales, the fund retains a substantial indirect holding of 855,926 shares, and Bloch directly holds 71,594 shares. Bloch disclaims beneficial ownership of the Canaan-held shares beyond any pecuniary interest and did not participate in the investment decision for these sales.
Price to earnings forward of Liquidia Corporation – NASDAQ:LQDA
This article provides a financial snapshot for Liquidia Corporation (NASDAQ: LQDA), focusing on its forward price-to-earnings ratio. It indicates that the company is listed on the Nasdaq Stock Market under the Health Technology/Pharmaceuticals sector. The content appears to be a stub or a section from a larger financial data platform, showing no trades and market closed status at the time of publication.
Liquidia Corp outlines path in pulmonary hypertension as investors watch regulatory milestones
Liquidia Corp is leveraging its proprietary drug delivery technology to develop therapies for pulmonary hypertension, with a focus on optimizing existing treatments. Investors are closely monitoring regulatory milestones, such as clinical trial data and FDA approvals, and commercialization progress, including market access and funding, which are crucial for the company's long-term growth in this specialized biopharmaceutical sector. The company's stock represents a typical risk-reward profile for a development-stage biotech, with performance tied to regulatory decisions and commercial readiness.
LQDA - Liquidia Corp Options
This article provides a detailed financial overview of Liquidia Corp (LQDA), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation ratios, growth rates, and market indicators, alongside a promotional offer for Finviz Elite services.
Is Liquidia’s Broad Russell Index Removal Reshaping The Investment Case For Liquidia (LQDA)?
Liquidia Corporation was removed from several Russell indices in late June 2026, which may affect its trading liquidity but not its core business. The company's investment case remains focused on YUTREPIA's commercial momentum, manufacturing expansion, and pipeline investment, supported by strong Q1 2026 earnings. Liquidia's narrative projects significant revenue and earnings growth by 2029, though some analysts are more cautious.
Enterprise value to EBIT forward of Liquidia Corporation – NASDAQ:LQDA
This article focuses on the enterprise value to EBIT forward of Liquidia Corporation (NASDAQ: LQDA). It briefly outlines where to find financial information for the company on TradingView, covering market data, financials, and other related investment tools. The content emphasizes that additional details are available via FactSet and other financial data providers.
Liquidia Technologies stock hits all-time high at 79.55 USD
Liquidia Technologies (LQDA) stock reached an all-time high of $79.55, currently trading at $79.40. The company has seen significant growth with a 1-year stock price increase of 555.33% and revenue growth of 1,937% in the last twelve months as of Q1 2026. This surge follows positive analyst sentiment and a favorable Supreme Court ruling, leading to its upcoming inclusion in the S&P SmallCap 600 Index.
Liquidia Corp (LQDA) Shares Fall 3.9% -- What GF Score of 67 Tells Investors
Liquidia Corp (LQDA) shares experienced a 3.9% drop to $75.16, yet GuruFocus assesses the stock as 65.7% undervalued with a GF Value™ of $218.97, despite a GF Score™ of 67/100 indicating above-average potential for long-term returns. However, the "value trap" warning and significant insider selling raise concerns for potential investors, suggesting a need for thorough financial and market condition assessment. The company shows strong growth prospects (Growth 10/10) but a weak valuation rank (2/10), complicated by a current P/E ratio significantly higher than its historical median.
Liquidia Corporation Stock 12‑Month Price Target Raised to $74.25, Implies 5% Downside
Liquidia Corporation's average 12-month price target has increased to $74.25 from $72.38, according to eight analysts' estimates. This new target implies a potential 5% downside based on the June 26 closing price. The consensus rating for LQDA remains "Buy," with analyst forecasts ranging from $60 to $109 per share.
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
This article highlights five significant analyst downgrades that occurred on Monday. Analysts from B of A Securities and Seaport Global changed their ratings for Liquidia Corp, Doximity Inc, Amphastar Pharmaceuticals, Inc, Madison Square Garden Entertainment Corp, and Alkermes Plc, impacting their price targets and investment outlooks.
Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell 3000E Growth Benchmark
Liquidia Corporation (NasdaqCM: LQDA) has been removed from the Russell 3000E Growth Benchmark.
LQDA Forecast — Price Target — Prediction for 2027
This article provides a forecast for Liquidia Corporation (LQDA) stock, including analyst price targets and ratings. It details the stock's current price, historical performance, volatility, market capitalization, and upcoming earnings report. The piece also includes financial metrics like EPS, revenue, net income, and EBITDA, along with guidance on how to buy the stock and its technical analysis ratings.
Liquidia reports Q1 profit, sales surge 44% sequentially
Liquidia Corporation reported its third consecutive profitable quarter with Q1 2026 net product sales surging 44% sequentially to $129.9 million. The company achieved a net income of $52.9 million and increased its cash reserves to $222.8 million. Liquidia is funding its growth and expansion, including clinical trials for L606 and new indications, through operating cash flow and aims for $1 billion in net revenue by 2027.
Liquidia Corp (LQDA) Institutional Confidence
This article analyzes the institutional confidence in Liquidia Corp (LQDA), assigning it a score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion stands at 73.52%, a slight increase quarter-over-quarter. It details the largest institutional shareholders and their recent activity in LQDA shares.
Is Liquidia Corporation's Recent Momentum Sustainable
Liquidia Corporation (LQDA) is experiencing significant financial and commercial success, driven by its pulmonary hypertension drug, YUTREPIA, which generated a 1031.2% revenue surge in 2025 and led to two consecutive profitable quarters. Despite this strong performance and a robust pipeline, the company faces substantial risks from ongoing patent litigation with United Therapeutics and a high reliance on YUTREPIA for its revenue. Investors are watching closely for continued YUTREPIA growth, advancements in its L606 pipeline candidate, and the outcome of the legal battle, all of which will determine the sustainability of its momentum.
Hedge Fund and Insider Trading News: Ken Griffin, Boaz Weinstein, Bill Ackman, Ray Dalio, OrbiMed Advisors, Liquidia Corp (LQDA), La-Z-Boy Inc (LZB), and More
This article provides a compilation of recent hedge fund and insider trading news involving prominent figures such as Ken Griffin, Boaz Weinstein, Bill Ackman, and Ray Dalio. Key updates include Griffin's philanthropic activities, Weinstein's valuation views, Ackman's fund holdings, and Dalio's management advice. Additionally, the article highlights significant insider transactions, including a large sale by a board member of Liquidia Corp (LQDA) and the CEO of La-Z-Boy Inc (LZB) selling shares.
Liquidia | 8-K: Liquidia Corporation Reports First Quarter 2026 Financial Results
This article is an 8-K filing from Liquidia Corporation, announcing their financial results for the first quarter of 2026. The content indicates a formal corporate disclosure regarding their latest financial performance.
Liquidia director Stephen Bloch sells $7.57m in common stock By Investing.com
Liquidia Corp Director Stephen Bloch recently sold approximately $7.57 million in company stock, occurring on June 22, 2026, while the stock traded near its 52-week high. These sales were made through Canaan VIII L.P., and Bloch disclaims beneficial ownership beyond his pecuniary interest. This news follows Liquidia's inclusion in the S&P SmallCap 600 Index and positive analyst ratings after a Supreme Court ruling.
Liquidia director Stephen Bloch sells $7.57m in common stock
Liquidia director Stephen Bloch sold approximately $7.57 million worth of common stock on June 22, 2026, which included indirectly held shares by Canaan VIII L.P. and some of his direct holdings. This sale occurred as Liquidia stock neared its 52-week high, following significant gains and amidst recent inclusion in the S&P SmallCap 600 Index and positive analyst ratings after a favorable Supreme Court ruling. Bloch disclaimed beneficial ownership of many of the sold securities, noting a communications-screen policy within Canaan Entities.
Liquidia(LQDA.US) Director Sells US$7.57 Million in Common Stock
Liquidia(LQDA.US) Director, Ben Machielse, sold 875,000 shares of common stock on June 21, at an average price of $8.65, totaling $7.57 million. This transaction reduced Machielse's direct holdings to 35,000 shares, representing 0.05% of the company's total outstanding shares. The stock's price has shown varied performance, with a 5-day increase but a yearly decline.
Fund tied to Liquidia (LQDA) director sells 100,000 common shares
An investment fund associated with Liquidia Corp director Stephen M. Bloch, Canaan VIII L.P., sold 100,000 shares of Liquidia common stock on June 22, 2026, for approximately $7.57 million. The sales occurred at weighted average prices of $75.5437 and $76.1776 per share. Although associated with a director, the transactions are characterized as fund-level activity, and Bloch disclaims beneficial ownership beyond his pecuniary interest, noting he did not participate in the decision.
Liquidia and Goodyear have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research identifies Liquidia Corp. (LQDA) as the Bull of the Day due to strong earnings estimate revisions, accelerating commercial launch of its lead product YUTREPIA, and positive technical momentum. Conversely, Goodyear (GT) is named the Bear of the Day, struggling with negative growth, inconsistent profitability, a highly leveraged balance sheet, and a downtrend towards multi-decade lows. The article also provides a positive outlook for Micron Technology, Inc. (MU) ahead of its Q3 earnings, citing high demand for its HBM chips driven by AI infrastructure spending and attractive valuation.
Liquidia and Goodyear have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research has named Liquidia Corp. (LQDA) as its Bull of the Day due to its strong growth catalysts in the biopharmaceutical sector, including its lead product YUTREPIA, positive earnings estimate revisions, and strong stock momentum. Conversely, Goodyear (GT) has been highlighted as the Bear of the Day, struggling with negative growth, inconsistent profitability, a highly leveraged balance sheet, and poor stock performance, alongside significant earnings downgrades. The article also provides a detailed analysis of Micron Technology, Inc. (MU) ahead of its Q3 earnings, noting strong growth prospects driven by AI-related memory demand.
Bull of the Day: Liquidia Corporation (LQDA)
Liquidia Corporation (LQDA) is highlighted as the "Bull of the Day" due to its promising position in the biopharmaceutical market, particularly with its lead product YUTREPIA for rare cardiopulmonary diseases. The company shows strong financials, including significant earnings estimate revisions, projected sales growth of over 300% this year, and a reasonable valuation despite a recent rally. Analysts note a compelling technical breakout, suggesting continued upward momentum for the stock.
Liquidia Corp (LQDA) Stock Up 6.3% and Still Undervalued -- GF S
Liquidia Corp (LQDA) shares spiked by 6.3% to $75.44, yet GuruFocus assesses it as significantly undervalued with a GF Value™ of $215.28, implying a 65.0% upside. Despite this, the stock is flagged as a "possible value trap" due to a low valuation rank and considerable insider selling. This suggests that while the price appears low, underlying fundamentals and strong insider selling trends warrant caution for investors.
Liquidia (LQDA) Presented New YUTREPIA Data With A Closer Look At Caregivers
Liquidia presented new clinical data for its inhaled treprostinil, YUTREPIA, at a pulmonary hypertension conference, focusing on patient reported outcomes, caregiver mental health, and the pharmacist's role. This data provides further context on YUTREPIA's real-world impact beyond efficacy and safety for investors. The company's stock has seen significant gains, and this broader clinical narrative will be important for future regulatory milestones and treatment adoption.
David Johnson of Liquidia (LQDA) awarded 5,882 common shares
Liquidia director David Johnson was granted 5,882 shares of common stock at no cost, which are restricted stock units (RSUs) that convert one-for-one into common stock. These RSUs will vest upon the earlier of one year from the grant date or the day before Liquidia's next annual shareholder meeting. Johnson is deemed to hold these securities for the benefit of Caligan-managed funds and accounts, which also indirectly hold a significant stake of 8,157,347 common shares.
Liquidia (NASDAQ: LQDA) director receives 5,882 RSUs equity award
Liquidia director Paul B. Manning was granted 5,882 restricted stock units (RSUs). These RSUs convert to common stock on a one-for-one basis and will vest either one year from the grant date or the day before the next annual shareholder meeting. Following this award, Manning directly holds 475,465 common stock shares, with additional indirect holdings through various entities.
Liquidia Corp (LQDA) director receives 5,882-share RSU equity grant
Liquidia Corp director Raman Singh was granted 5,882 Restricted Stock Units (RSUs) as an equity award, with no cash paid per share. This grant increases his direct holdings to 44,637 shares. The RSUs convert to common stock on a one-for-one basis and will vest either one year from the grant date or just before the company's next annual shareholder meeting.
Liquidia Corp (LQDA) director granted 5,882 RSUs in new equity award
Liquidia Corp director Damian deGoa was granted 5,882 Restricted Stock Units (RSUs) as part of his compensation, which will convert into common stock on a one-for-one basis. These RSUs were awarded with a stated price of $0.00 per share and will vest upon the earlier of one year from the grant date or the day before the company's next annual shareholder meeting. Following this award, deGoa directly holds 92,353 shares of Liquidia Common Stock.
Liquidia (LQDA) director granted 5,882 RSUs tied to board service
Liquidia Corp director Joanna Horobin was granted 5,882 Restricted Stock Units (RSUs) as an equity award, which convert to common stock on a one-for-one basis at no purchase price. This award increases her direct ownership to 39,637 shares. The RSUs are tied to her continued board service, vesting on the earlier of one year from the grant date or the day before Liquidia’s next annual shareholder meeting.
Liquidia (LQDA) director Stephen Bloch granted 5,882 RSU shares in equity award
Liquidia Corp director Stephen M. Bloch was granted 5,882 Restricted Stock Units (RSUs) which convert to common stock at $0.00 per share. These RSUs will vest upon the earlier of one year from the grant date or the day before the next annual shareholder meeting. Following this grant, Bloch directly holds 71,594 shares, with an additional 980,073 shares held indirectly through Canaan entities.
Director at Liquidia (NASDAQ: LQDA) granted 5,882 RSUs in stock award
Liquidia Corp director Arthur S. Kirsch was granted 5,882 Restricted Stock Units (RSUs) on June 16, 2026, as a compensation-related award. These RSUs convert into common stock on a one-for-one basis and will vest on the earlier of the one-year anniversary of the grant date or the day prior to Liquidia's next annual shareholder meeting. Following this transaction, Kirsch directly holds 46,637 shares of Liquidia common stock.
Liquidia (LQDA) director receives 5,882-share equity grant in latest Form 4
Liquidia Corp director Katherine Rielly-Gauvin was granted 5,882 shares of common stock as an equity award, with a grant price of $0.00 per share, indicating it is compensation-related. Following this transaction, she directly holds 44,637 shares. The restricted stock units (RSUs) will vest on the earlier of one year from the grant date or the day before Liquidia's next annual shareholder meeting.
Liquidia Corp (LQDA) Financial Health: Profitability & Balance Sheet Analysis
Liquidia Corp (LQDA) showcases robust financial health, ranking 18th out of 157 in the Pharmaceuticals industry with a financial score of 9.01. The company reported a significant year-over-year revenue increase of 4158.49% to $132.87M and a net profit increase of 237.78%. This strong performance highlights high operating efficiency and growth potential.
Liquidia Corporation Files Form 8-K: Key Details from Latest SEC Filing for 2026
Liquidia Corporation announced the results of its 2026 Annual Meeting of Stockholders, where shareholders elected three Class II directors, ratified PricewaterhouseCoopers LLP as their independent auditor, and approved executive compensation by non-binding advisory vote. The company noted no pending mergers or acquisitions and indicated it no longer qualifies as an emerging growth company. While significant for governance, the meeting yielded no new material developments expected to immediately impact the stock price.
Strong backing as Liquidia (NASDAQ: LQDA) holders approve board, auditor and pay
Liquidia Corporation announced the results of its annual meeting, where shareholders approved the election of three Class II directors, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and endorsed the compensation of named executive officers through a non-binding advisory vote. A quorum was established with 67,479,187 shares represented out of 88,893,621 eligible shares outstanding, reflecting strong shareholder participation and support for the company's proposals.
Board Member At Liquidia Sells $14.01M Of Stock
A board member at Liquidia (NASDAQ: LQDA), Stephen M Bloch, sold 196,111 shares worth $14.01 million on June 16, according to an SEC filing. Despite this insider sale, Liquidia's shares were up by 0.96% as of Wednesday morning. The company shows positive revenue growth of 4158.49%, an excellent gross margin of 91.08%, but faces challenges with debt management and a lower-than-average EPS.
Liquidia Corp (LQDA) Stock Down 5.3% -- Now Undervalued? GF Scor
Liquidia Corp (LQDA) saw its stock fall by 5.3% to $68.01, yet GuruFocus's GF Value™ suggests it is 67.8% undervalued at $210.93, indicating potential upside. Despite a GF Score™ of 68/100, which highlights strong growth and moderate financial strength, the stock is flagged as a "Possible Value Trap" due to a low valuation rank and significant insider selling totaling $125.3 million in the last three months. Investors are cautioned to conduct thorough due diligence given the mixed signals from valuation models and insider activity.
Canaan entities tied to Liquidia (NASDAQ: LQDA) sell 196K shares in market trades
Entities linked to Liquidia director Stephen M. Bloch, specifically Canaan VIII L.P. and Canaan Partners VIII LLC, sold 196,111 shares of Liquidia common stock in open-market transactions on June 12 and June 15, 2026. The shares were sold at weighted average prices between approximately $71 and $72 per share. Bloch disclaims beneficial ownership beyond his pecuniary interest, and a communications-screen policy ensured he did not participate in the investment decision.
Liquidia (LQDA) HR chief sells 24,880 shares under 10b5-1 plan
Liquidia Corp's Chief Human Resource Officer, Sarah Krepp, sold 24,880 shares of common stock on June 11, 2026, at a volume-weighted average price of $70.2784 per share. These sales were conducted under a Rule 10b5-1 trading plan adopted on March 12, 2026, and involved shares acquired through the company's 2020 Employee Stock Purchase Plan. Krepp retains significant unvested Restricted Stock Units from prior grants, indicating ongoing equity exposure.
[Form 4] Liquidia Corp Insider Trading Activity
A Form 4 filing for Liquidia Corp (LQDA) revealed significant insider selling activity. Canaan VIII L.P., an investment entity associated with director Stephen M. Bloch, sold 388,223 shares of Liquidia common stock between June 10 and June 11, 2026, at prices ranging from $64.00 to $72.48 per share. While Bloch disclaims beneficial ownership of these specific sales, the transactions reflect a venture fund reducing its exposure to Liquidia, even as Bloch maintains a separate direct holding of 65,712 shares.
Liquidia (LQDA) Is Up 15.8% After S&P SmallCap 600 Addition And New YUTREPIA Data - What's Changed
Liquidia Corporation (LQDA) saw a 15.8% stock increase following its inclusion in the S&P SmallCap 600 Index and the presentation of new data for its YUTREPIA inhalation powder. The new ASCENT study data, presented at the PHA 2026 conference, detailed patient-reported outcomes for YUTREPIA in pulmonary hypertension associated with interstitial lung disease. While the index inclusion could expand its shareholder base, the company's investment narrative remains heavily reliant on YUTREPIA's sustained growth and execution.
Caregivers’ mental health in focus as Liquidia takes PH research to Dallas
Liquidia (NASDAQ:LQDA) will present four posters at the PHA 2026 International PH Conference and Scientific Sessions, focusing on YUTREPIA data for PH-ILD, patient-reported cough outcomes, caregiver mental health challenges, and pharmacists' roles in PH care teams. The company aims to highlight its commitment to patients and caregivers by sharing research that addresses both clinical aspects and the broader impact of pulmonary hypertension. This news follows a pattern of positive market reactions to Liquidia's announcements, with the stock gaining 9.77% on the day this information was published.
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
Liquidia Corporation announced its upcoming inclusion in the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026. This inclusion recognizes the company's progress and reflects its commitment to patients, innovation, and operational excellence. Liquidia is a biopharmaceutical company focused on revolutionizing care for respiratory and vascular diseases using its proprietary PRINT® technology.
LQDA (NASDAQ) Rule 144 notice lists 3 recent dispositions by affiliate
A recently filed Rule 144 notice for Liquidia Corp (LQDA) indicates proposed sales of common stock related to employee plans and restricted stock units. The filing also discloses three past dispositions by Sarah Krepp, an affiliate, totaling 276, 4,557, and 16,261 shares on June 1, 2026, April 13, 2026, and March 13, 2026, respectively, with associated proceeds. This filing provides details on securities to be sold and recent transactions by an affiliate, highlighting potential future sales and past activity.
[Form 4] Liquidia Corp Insider Trading Activity
A fund linked to Liquidia Corp director Stephen M. Bloch sold 220,835 shares of Liquidia common stock on June 8 and June 9 at weighted average prices between $64 and $66 per share. Although Bloch is a director, he disclaims beneficial ownership of these shares and did not participate in the investment decision due to a communications-screen policy. Following these transactions, Bloch directly holds 65,712 Liquidia shares.
Insider Selling: Stephen M Bloch Unloads $14.27M Of Liquidia Stock
Stephen M. Bloch, a Board Member at Liquidia (NASDAQ: LQDA), recently sold 220,835 shares of the company's stock for a total of $14.27 million. This insider transaction comes as Liquidia's shares were up 6.89% to $69.75. The article also highlights Liquidia's strong revenue growth, high debt-to-equity ratio, and premium valuation metrics compared to industry averages.
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
Liquidia Corporation announced it will present four posters at the PHA 2026 International PH Conference and Scientific Sessions, taking place June 11-14 in Dallas. The presentations will include data from its ASCENT study of YUTREPIA® inhalation powder, focusing on patient-reported cough outcomes and insights into the mental health burden on caregivers of PH patients. This research highlights Liquidia's commitment to understanding the full scope of living with pulmonary hypertension.
